Will EU Regulatory Battles Over Endocrine Disruptors Translate to US Litigation?

Posted by David Schwartz on Posted on

There is a battle raging in the European Union on an issue that is recognized in the US only by environmental scientists, policy wonks, and activists: the regulatory status of endocrine disrupting chemicals. As we have written before, this debate could have dramatic implications for litigation in the US. Such litigation could involve claims that
Read More

USING GENOMICS TO PREVAIL IN YOUR NEXT TOXIC TORT CASE

Posted by David Schwartz on Posted on

As any good toxic tort litigator knows, it is not enough for a defendant to demonstrate that the alleged harmful chemical was not the cause of the injury. Rather, an effective defense provides the jury with a reasonable explanation as to what the cause of the injury was. Genomic data offer the defense just such
Read More

WEBINAR: Genetic Susceptibility, Exposure Markers, and the Talc Experience

Posted by David Schwartz on Posted on

Innovative Science Solutions will be speaking at the upcoming Toxic Torts and Product Liability Webinar to be hosted by Mayer Brown on Thursday, January 19, 2017 (1:00 p.m. – 2:30 p.m. EST). Emerging Science and Toxic Tort Litigation: Genetic Susceptibility, Exposure Markers, and the Talc Experience The webinar features a presentation by Dr. Suresh Moolgavkar
Read More

Does Carcinogenicity Classification Make Any Sense?

Posted by David Schwartz on Posted on

In a recent trial involving allegations that asbestos-contaminated talc caused the plaintiff’s mesothelioma (the Lamonica case), plaintiff counsel (Scott Frost) was having a difficult time impeaching the opinions of the defense pathologist (Dr. Mossman). After spending some time trying to impeach her opinions based on her financial payments, Frost turned to another tried and true
Read More

Jurors in Toxic Tort Litigation Take Genetic Issues Seriously

Posted by David Schwartz on Posted on

This article was authored by David Schwartz, PhD and Kirk Hartley, Esq.  This post previously appeared on The Goldberg Segalla Asbestos Case Tracker.
Read More

The Increasing Relevance of Social Media to Adverse Drug Reaction Reporting

Posted by David Schwartz on Posted on

Adverse event data from protocol-driven, controlled clinical trials forms the backbone of any rigorous safety assessment on a new drug product. Nevertheless, lawyers defending pharmaceutical agents in product liability litigation must maintain a detailed awareness of spontaneously reported adverse events associated with drug exposures. As part of this effort, a good litigator must develop an
Read More

Big Data and New Technology – ISS Presenting at The 10th Annual Gibbons E-Discovery Conference

Posted by David Schwartz on Posted on

Dr. David Schwartz of Innovative Science Solutions will be presenting at the upcoming 10th Annual Gibbons E-Discovery Conference being held in West Orange (New Jersey) on November 18, 2016. 
Read More

Follow the Science Not the Money

Posted by David Schwartz on Posted on

This post was authored by Joseph Huggard, the General Manager of The Huggard Consulting Group who has spent more than 20 years working on a broad range of high profile issues with a particular emphasis on the use and communication of robust science, better regulation and regulatory impact assessment. Joe is highly regarded for his
Read More

The Future of Asbestos Litigation – Linking Genomic Science with Rigorous Exposure Assessment

Posted by David Schwartz on Posted on

The vast majority of malignant mesothelioma (MM) cases are asbestos related, yet the majority of individuals exposed to asbestos (even relatively high doses of amphibole asbestos fibers) do not develop MM. Many have concluded from this observation that there may be some genetic factor or factors that make some individuals more prone to mesothelioma than
Read More

new report:  asbestos science for toxic tort lawyers (2nd Edition released)

Posted by David Schwartz on Posted on

As we have highlighted in our blog over the past couple of years, there is a revolution underway in toxic tort litigation. This revolution involves the use of genomic data to define tumor types, to establish causation, and to establish alternate cause arguments. Genomic and other molecular science findings and legal issues continue to take on additional
Read More